Rabeprazole Sodium (EC) & Domperidone Sustained Release Capsules – RAQUIL 40 DSR

Rabeprazole Sodium (EC) & Domperidone Sustained Release Capsules – Acid Reflux Control with Enhanced Gastric Motility.

RAQUIL 40 DSR: The Dual composition of Rabeprazole 40mg + Domperidone 30mg Sustained Release effectively treats acid reflux, GERD, and motility disorders, and Rabeprazole is a proton pump inhibitor (PPI) that reduces stomach acid production by inhibiting the H+/K+ ATPase pump, preventing acid reflux, heartburn, and ulcer formation. Domperidone is a prokinetic agent that accelerates gastric emptying and prevents acid regurgitation, reducing bloating, nausea, and reflux symptoms.

Recommended By Specialists:
Gastroenterologists: It is prefer to treat the disease associated with GERD, peptic ulcers, and chronic acid reflux.
General Physicians: It is preferred to treat the disease associated with common acid-peptic disorders and indigestion.
Internal Medicine Specialists: It is preferred to treat the disease associated with long-term management of GERD/dyspepsia.

Key benefits of Rabeprazole Sodium (EC) & Domperidone Sustained Release Capsules – RAQUIL 40 DSR:
Dual-Action for Acid Suppression & Gastric Motility – Rabeprazole controls excessive acid secretion, while Domperidone enhances gastric emptying, reducing acid reflux and bloating.
Superior to PPIs Alone – Addresses both acid-related disorders and motility dysfunction, providing comprehensive relief from GERD and dyspepsia.
Sustained-Release Formula for Long-Lasting Effect – Ensures extended symptom relief, reducing the need for frequent dosing and enhancing patient compliance.

INDICATIONS:
Gastroesophageal Reflux Disease (GERD)
Acid Peptic Disorders
Chronic Dyspepsia
Delayed Gastric Emptying
Recurrent Nausea & Bloating*